



SARS-CoV-2 Variants Research and Vaccines

Guest Editors:

Prof. Dr. Ahmed O. Kaseb

Department of Gastrointestinal
Medical Oncology, The University
of Texas MD Anderson Cancer
Center, Houston, TX 77030, USA

Dr. Hassan Bencheqroun

RESPIRE Clinical Research, Palm
Springs, CA 92262, USA

Deadline for manuscript
submissions:

closed (20 November 2023)

Message from the Guest Editors

Over the span of more than two years since the beginning of the COVID-19 pandemic, the world has witnessed the evolution of the virus through different variants which have affected global communities in many different ways to the original virus. These variants have also caused different symptoms and differences in the make-up of the infected individuals.

As we await the endemicity of COVID-19, waves of new variants are producing new symptoms and making multiple treatments, which were thought to be lifesaving in their inception, obsolete. Clinical trials must anticipate the future landscape that is likely to exist when they are able to be implemented in an ever-changing patient profile and attitude towards research.

This Special Issue, which is dedicated to COVID-19 two years on, will consider submissions regarding topics such as prognostic indicators of COVID-19 infections, the global heterogeneity of patients affected by local variants of the SARS-CoV2 virus, the evolving approaches to diagnosis, treatment, and prevention (including masks and vaccines), along with future directions in these respective themes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Lawrence S. Young

Warwick Medical School,
University of Warwick, Coventry
CV4 7AL, UK

Message from the Editor-in-Chief

The worldwide impact of infectious disease is incalculable. The consequences for human health in terms of morbidity and mortality are obvious and vast but, when infections of animals and plants are also taken into account, it is hard to imagine any other disease that has such a significant impact on our lives—on healthcare systems, on agriculture and on world economics. *Pathogens* is proud to continue to serve the international community by publishing high quality studies that further our understanding of infection and have meaningful consequences for disease intervention.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PubAg, CaPlus / SciFinder, AGRIS, and other databases.

Journal Rank: JCR - Q2 (*Microbiology*) / CiteScore - Q2 (*General Immunology and Microbiology*)

Contact Us

Pathogens Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pathogens
pathogens@mdpi.com
[X@Pathogens_MDPI](https://twitter.com/Pathogens_MDPI)